title: Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.
abstract: Induction of apoptosis plays a crucial role in the response of tumors to treatment. Thus, we investigated the pharmacodynamics and tumor saturation kinetics of a death receptor 5 antibody (anti-DR5) when combined with chemotherapeutics. For our investigations, we applied an imaging method that allows monitoring of apoptosis noninvasively in living mice. A stably transfected apoptosis reporter based on split luciferase technology facilitates to screen various chemotherapeutics and anti-DR5 on their ability to induce apoptosis in glioblastoma cells in vitro as well as in vivo. We found that doxorubicin (DOX) treatment in vitro led to significant apoptosis induction within 48 hours and to a 2.3-fold increased anti-DR5 binding to the cell surface. In contrast, cisplatin and 5-fluorouracil (5-FU) treatment altered anti-DR5 binding only marginally. Induction of apoptosis by treatment with anti-DR5 was dose- and time-dependent (both in vitro and in vivo). Simultaneous visualization of fluorescence-labeled anti-DR5 in tumor tissue and apoptosis revealed maximal apoptosis induction immediately after the compound had reached tumor site. Regarding combination therapy of anti-DR5 and DOX, we found that the sequential application of DOX before anti-DR5 resulted in synergistically enhanced apoptosis reporter activity. In striking contrast, anti-DR5 given before DOX did not lead to increased apoptosis induction. We suggest that DOX-induced recruitment of DR5 to the cell surface impacts the enhanced apoptotic effect that can be longitudinally monitored by apoptosis imaging. This study demonstrates that the combination of apoptosis and fluorescence imaging is an excellent method for optimizing dosing and treatment schedules in preclinical cancer models.
authors.affiliation: Pharma Research and Early Development, Discovery Oncology, Roche Diagnostics GmbH, Penzberg, Germany. thomas.weber.tw7@roche.com
authors.forename: Thomas G
authors.initials: TG
authors.lastname: Weber
authors.forename: Thomas
authors.initials: T
authors.lastname: Pöschinger
authors.forename: Stefanie
authors.initials: S
authors.lastname: Galbán
authors.forename: Alnawaz
authors.initials: A
authors.lastname: Rehemtulla
authors.forename: Werner
authors.initials: W
authors.lastname: Scheuer
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects*; D015153:Blotting, Western; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D005909:Glioblastoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D057809:HEK293 Cells; D006801:Humans; D008163:Luminescent Measurements / Q000379:methods; D051379:Mice; D008812:Mice, Hairless; D016513:Mice, SCID; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000276:immunology* / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
chemical_list: D000911:Antibodies, Monoclonal; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D004317:Doxorubicin; D002945:Cisplatin; D005472:Fluorouracil
references.citation: Cancer Lett. 2002 Jan 10;175(1):27-38
references.pmid: 11734333
references.citation: Cancer Lett. 2008 May 8;263(1):14-25
references.pmid: 18329793
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2492-501
references.pmid: 18413842
references.citation: PLoS One. 2012;7(5):e35830
references.pmid: 22615740
references.citation: Rev Recent Clin Trials. 2009 Jan;4(1):34-41
references.pmid: 19149761
references.citation: Cell. 2012 May 11;149(4):780-94
references.pmid: 22579283
references.citation: Cell Res. 2000 Sep;10(3):161-7
references.pmid: 11032168
references.citation: J Immunol. 2000 Apr 15;164(8):3961-70
references.pmid: 10754286
references.citation: Cancer Res. 1999 Feb 1;59(3):734-41
references.pmid: 9973225
references.citation: Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):507-16
references.pmid: 18474311
references.citation: Clin Cancer Res. 2010 May 1;16(9):2591-604
references.pmid: 20406839
references.citation: Cancer Res. 2003 Sep 1;63(17):5390-400
references.pmid: 14500373
references.citation: Cancer Invest. 2011 Oct;29(8):511-20
references.pmid: 21877938
references.citation: Cancer Res. 1998 Dec 1;58(23):5315-20
references.pmid: 9850056
references.citation: Cancer Res. 1998 Apr 15;58(8):1593-8
references.pmid: 9563466
references.citation: Ann N Y Acad Sci. 2003 Dec;1010:1-8
references.pmid: 15033687
references.citation: Oncogene. 2013 Jun 6;32(23):2818-27
references.pmid: 22824792
references.citation: Oncogene. 2004 Jan 15;23(2):446-56
references.pmid: 14724573
references.citation: Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31
references.pmid: 18495520
references.citation: Cancer Res. 2002 Apr 15;62(8):2272-80
references.pmid: 11956083
references.citation: J Biol Chem. 2002 Dec 27;277(52):50842-54
references.pmid: 12407106
references.citation: Cell Death Differ. 2004 Aug;11(8):915-23
references.pmid: 15118763
references.citation: Oncogene. 2002 Apr 18;21(17):2623-33
references.pmid: 11965535
references.citation: Trends Mol Med. 2006 Sep;12(9):440-50
references.pmid: 16899408
references.citation: Clin Cancer Res. 2010 Mar 15;16(6):1701-8
references.pmid: 20197482
references.citation: Oncogene. 2006 Aug 7;25(34):4798-811
references.pmid: 16892092
references.citation: Mol Cell Biol. 2001 May;21(9):3025-36
references.pmid: 11287608
references.citation: Int J Mol Sci. 2012;13(7):7886-901
references.pmid: 22942679
references.citation: J Neurooncol. 2012 Apr;107(2):359-64
references.pmid: 22045118
references.citation: Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48
references.pmid: 12787570
references.citation: FEBS J. 2008 Apr;275(8):1925-36
references.pmid: 18341587
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):1998-2009
references.pmid: 19276263
references.citation: Clin Cancer Res. 2002 Mar;8(3):691-7
references.pmid: 11895897
references.citation: Cancer Invest. 2012 Dec;30(10):727-31
references.pmid: 23061802
references.citation: J Control Release. 2011 Aug 25;154(1):93-102
references.pmid: 21609741
references.citation: Cancer Gene Ther. 2005 Mar;12(3):228-37
references.pmid: 15550937
references.citation: Eur J Pharmacol. 2009 Dec 25;625(1-3):63-72
references.pmid: 19836385
references.citation: Mol Imaging Biol. 2013 Feb;15(1):28-39
references.pmid: 22528864
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Cell Death Differ. 2008 Apr;15(4):751-61
references.pmid: 18219321
references.citation: Prostate. 2005 Feb 1;62(2):165-86
references.pmid: 15389801
references.citation: PLoS One. 2013 Jun 11;8(6):e66248
references.pmid: 23776643